MAR Stock Overview
A life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Maravai LifeSciences Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.86 |
| 52 Week High | US$10.40 |
| 52 Week Low | US$1.47 |
| Beta | 0.19 |
| 1 Month Change | 22.37% |
| 3 Month Change | -53.73% |
| 1 Year Change | -81.94% |
| 3 Year Change | -94.10% |
| 5 Year Change | n/a |
| Change since IPO | -93.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| MAR | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 6.3% | -0.5% | 0.8% |
| 1Y | -81.9% | -5.6% | 14.6% |
Return vs Industry: MAR underperformed the German Life Sciences industry which returned -5.6% over the past year.
Return vs Market: MAR underperformed the German Market which returned 14.6% over the past year.
Price Volatility
| MAR volatility | |
|---|---|
| MAR Average Weekly Movement | 13.9% |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: MAR's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: MAR's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 580 | Trey Martin | www.maravai.com |
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).
Maravai LifeSciences Holdings, Inc. Fundamentals Summary
| MAR fundamental statistics | |
|---|---|
| Market cap | €271.18m |
| Earnings (TTM) | -€145.94m |
| Revenue (TTM) | €216.92m |
1.3x
P/S Ratio-1.9x
P/E RatioIs MAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAR income statement (TTM) | |
|---|---|
| Revenue | US$241.86m |
| Cost of Revenue | US$151.67m |
| Gross Profit | US$90.19m |
| Other Expenses | US$252.90m |
| Earnings | -US$162.71m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.13 |
| Gross Margin | 37.29% |
| Net Profit Margin | -67.28% |
| Debt/Equity Ratio | 55.6% |
How did MAR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 15:12 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Maravai LifeSciences Holdings, Inc. is covered by 15 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Erin Wilson Wright | Credit Suisse |